STOCK TITAN

Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Repare Therapeutics (Nasdaq: RPTX) announced that its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on April 20 at 9:30 a.m. ET. Investors can access a live webcast of the presentation through the Company’s website, with a replay available for 30 days following the event.

The Company specializes in precision oncology using a proprietary synthetic lethality approach, with notable products in development, including the ATR inhibitor RP-3500 and the PKMYT1 inhibitor RP-6306.

Positive
  • None.
Negative
  • None.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Tuesday, April 20 at 9:30 a.m. ET.

A live webcast of the presentation can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 30 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential best-in-class ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a first-in-class, selective, oral inhibitor of PKMYT1 to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers, and a Polθ inhibitor program. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

FAQ

When will Repare Therapeutics present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference?

Repare Therapeutics will present on April 20, 2021, at 9:30 a.m. ET.

How can I access the Repare Therapeutics conference presentation?

The presentation will be accessible via a live webcast on the Investor section of Repare Therapeutics' website.

What is the main focus of Repare Therapeutics?

Repare Therapeutics focuses on precision oncology through a proprietary synthetic lethality approach for developing novel therapeutics.

What are some key products in development by Repare Therapeutics?

Repare's pipeline includes the ATR inhibitor RP-3500 and the PKMYT1 inhibitor RP-6306, among others.

Is there a replay available for the Repare Therapeutics conference?

Yes, a replay of the webcast will be archived on the Company’s website for 30 days after the event.

Repare Therapeutics Inc. Common Shares

NASDAQ:RPTX

RPTX Rankings

RPTX Latest News

RPTX Stock Data

118.60M
38.71M
0.95%
83.62%
1.77%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAINT-LAURENT